Yu Chen, PhD, MD

Publications

2 grants

PI
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma
NCI · 2022–2027 · via NIH RePORTER
R01CA265026-04
MPI
SPORE in Prostate Cancer
NCI · 2001–2027 · via NIH RePORTER
P50CA092629-25

Completed grants (4)

PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine
NCI · 2019–2025 · via NIH RePORTER
U01CA224044-05
MPI
Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy
NCI · 2017–2023 · via NIH RePORTER
U54CA224079-04
PI
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance
NCI · 2017–2023 · via NIH RePORTER
R01CA208100-05
PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.
NCI · 2009–2014 · via NIH RePORTER
K08CA140946-05

Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 1999
Sloan Research Fellowship · Alfred P. Sloan Foundation · 1998

Weill Cornell Medicine Selected for Prostate Cancer Foundation Challenge Award
March 3, 2026
Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.
New Starr Cancer Consortium Grants Awarded to Weill Cornell Medicine Researchers
October 30, 2024
Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition
New Cancer Subtype May Illuminate Treatment Strategy
May 27, 2022
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.